This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bernard, S. Articles by Flockhart, D. A. Search for Related Content PubMed PubMed Citation Articles by Bernard, S. Articles by Flockhart, D. A.

Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications

^a Division of Hematology and Medical Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA; ^b Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Key Words. CYP2D6 polymorphism • Hepatic metabolism • 5-HT₃-receptor antagonist antiemetics • Genetic variability

Correspondence: S. Bernard, Division of Hematology and Medical Oncology, University of North Carolina School of Medicine, 3009 Old Clinic Building, CB #7305, Chapel Hill, North Carolina 27599-7305, USA. Telephone: 919-966-4431; Fax: 919-966-6735; e-mail: bernmed{at}med.unc.edu

DNA polymorphisms have been identified in the genes encoding a number of the cytochrome P450 (CYP) enzymes, leading to wide interindividual variation in drug clearance. CYP2D6 metabolizes a significant number of clinically used medications, and genetic variants of the CYP2D6 isozyme that result in varying levels of metabolic activity are of clinical importance in some settings. The exact nature of the clinical effect caused by polymorphisms of the gene depends on the drug in question and the specific variant alleles expressed, as individual variants result in differing phenotypes with a range of levels of enzymatic activity.

Compromised drug efficacy due to CYP2D6 variation has been documented with a variety of agents, and this review considers a number of examples, including the 5-HT₃-receptor antagonists, which are used in oncology supportive care for the prophylaxis of nausea and vomiting. CYP2D6 is involved in the metabolism of all of the most commonly available agents, except granisetron, and their efficacy and side effects may therefore be affected by the CYP2D6 polymorphism.

Significant interethnic differences in CYP2D6 allele frequencies have been demonstrated from studies across many countries. However, incidences of polymorphisms in the U.S. population have been challenging to characterize because of the country’s wide ethnic diversity. The CYP2D6 polymorphism may become more important as robust clinical tests become widely available and as the use of multiple medications and the attendant risk for drug–drug interactions increases.

This article has been cited by other articles:

				M. A. Adegbola Can Heterogeneity of Chronic Sickle-Cell Disease Pain Be Explained by Genomics? A Literature Review Biol Res Nurs, July 1, 2009; 11(1): 81 - 97. [Abstract] [PDF]

				M. Nielsen and N.V. Olsen Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting Br. J. Anaesth., October 1, 2008; 101(4): 441 - 445. [Full Text] [PDF]

				J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF]

				R. J Sullivan, E. H Hagen, and P. Hammerstein Revealing the paradox of drug reward in human evolution Proc R Soc B, June 7, 2008; 275(1640): 1231 - 1241. [Abstract] [Full Text] [PDF]

				A. Bhathena, T. Mueller, D. R. Grimm, K. Idler, A. Tsurutani, B. B. Spear, and D. A. Katz Frequency of the Frame-Shifting CYP2D7 138delT Polymorphism in a Large, Ethnically Diverse Sample Population Drug Metab. Dispos., August 1, 2007; 35(8): 1251 - 1253. [Abstract] [Full Text] [PDF]

				T. Gumbo, A. Louie, W. Liu, D. Brown, P. G. Ambrose, S. M. Bhavnani, and G. L. Drusano Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2329 - 2336. [Abstract] [Full Text] [PDF]